Teclistamab-associated adverse events: a disproportionality analysis of the FDA adverse event reporting system

Xiaoyu He, Gang Chen, Zhengyu Zhan, Zhenjiang Li

Open source

DOI
10.1080/16078454.2026.2730041
Published
2026-09-15
Container
Hematology
Publisher
Informa UK Limited
Open access
unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1080/16078454.2026.2730041,
  title = {Teclistamab-associated adverse events: a disproportionality analysis of the FDA adverse event reporting system},
  author = {Xiaoyu He and Gang Chen and Zhengyu Zhan and Zhenjiang Li},
  year = {2026},
  journal = {Hematology},
  doi = {10.1080/16078454.2026.2730041},
  url = {https://doi.org/10.1080/16078454.2026.2730041}
}

RIS

TY  - JOUR
TI  - Teclistamab-associated adverse events: a disproportionality analysis of the FDA adverse event reporting system
AU  - Xiaoyu He
AU  - Gang Chen
AU  - Zhengyu Zhan
AU  - Zhenjiang Li
PY  - 2026
JO  - Hematology
DO  - 10.1080/16078454.2026.2730041
UR  - https://doi.org/10.1080/16078454.2026.2730041
ER  - 

APA

He, X., Chen, G., Zhan, Z., & Li, Z. (2026). Teclistamab-associated adverse events: a disproportionality analysis of the FDA adverse event reporting system. Hematology. https://doi.org/10.1080/16078454.2026.2730041

Source records